Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00303290 · ClinicalTrials.gov registry record · Phase 1
PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML
A Phase 1 study of Chronic Myeloid Leukemia, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
- 1
- Study location
NCT00303290: Completed Phase 1 study of Chronic Myeloid Leukemia, sponsored by M.D. Anderson Cancer Center.
NCT00303290 is a Phase 1 study of Chronic Myeloid Leukemia that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 76 participants, below the 208-participant average among 35 other Chronic Myeloid Leukemia trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00303290, a Phase 1 study of Chronic Myeloid Leukemia, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to see if a new interferon which is given only once a week with ARA-C works as well as standard interferon and low dose ARA-C. The safety of this treatment will also be studied.
Primary Outcome
Cytogenetic responses evaluated by routine cytogenetics.
Conditions Studied
Interventions
- DRUG Peg Interferon Alpha 2b (Peg Intron)
- DRUG Ara-C (cytosine arabinoside)
Study Locations (1)
Texas
- The University of Texas M.D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2000-01 |
| Est. Completion | 2014-11 |
| Phase | Phase 1 |
What the finished NCT00303290 record still lists
NCT00303290 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 208-participant average among 35 other Chronic Myeloid Leukemia trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Chronic Myeloid Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Peg Interferon Alpha 2b (Peg Intron) is the first listed.
NCT00303290 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00303290 about?
NCT00303290 is a clinical study titled "PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML". The goal of this clinical research study is to see if a new interferon which is given only once a week with ARA-C works as well as standard interferon and low dose ARA-C. The safety of this treatment will also be studied.
What is the current status of trial NCT00303290?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2000-01. Estimated completion is 2014-11.
What conditions does trial NCT00303290 study?
This clinical trial studies the following conditions: Chronic Myeloid Leukemia.
What interventions are being tested in trial NCT00303290?
The interventions under investigation include: Peg Interferon Alpha 2b (Peg Intron) (DRUG), Ara-C (cytosine arabinoside) (DRUG).
Who is sponsoring clinical trial NCT00303290?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00303290 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00303290's enrollment target sits among peer trials
76 14th of 35 higher than 22 of 35 other Chronic Myeloid Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
RECRUITING · Phase 1
-
KRT-232 and TKI Study in Chronic Myeloid Leukemia
RECRUITING · Phase 1
-
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
RECRUITING · Phase 1
-
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
RECRUITING · Phase 1
-
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
RECRUITING · Phase 1
-
A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia